Compare · head to head
LENSAR vs Nukkleus
LENSAR ranks higher overall — 360 rank 88 vs 13.
LENSAR leads on Value (60 vs 39), Quality (48 vs 21), Safety (70 vs 43) and Sentiment (62 vs 51).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Software & Internet |
| Industry | Health Care Equipment & Supplies | Software |
| Size | Small | X-Small |
| ISIN | US52634L1089 | US67054R2031 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 88 | 13 |
| Value | 60 | 39 |
| Quality | 48 | 21 |
| Growth | 51 | NR |
| Safety | 70 | 43 |
| Sentiment | 62 | 51 |
| Quality details | ||
| Profitability | 59 | 24 |
| Cash Truth | 37 | 19 |
LENSAR vs NovLENSAR vs Pulse BiosciencesLENSAR vs Caris Life SciencesLENSAR vs Xeris PharmaceuticalsAdd a third stock →
Full analyses: LENSAR · Nukkleus
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100